http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013536425-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4712 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2011-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013536425-A |
| titleOfInvention | Use of biomarkers in the assessment of early transition from arterial hypertension to heart failure |
| abstract | The present invention relates to a method for diagnosing abnormalities in the function and / or structure of the heart prior to heart failure in a subject possessing risk factors for developing heart failure, comprising the following steps: a) obtained from the individual Measuring the concentration of at least one cardiac troponin in a sample; b) optionally measuring the concentration of one or more other heart failure markers in the sample; and c) the concentration measured in step (a) Functional and / or structural abnormalities are assessed by comparing the concentration (s), optionally measured in step (b), with the concentration of this marker or those markers established in the control sample. The present invention also relates to a method for predicting the risk that a subject having a risk factor for developing heart failure will suffer from heart failure, comprising the following steps: a) at least one in a sample obtained from the individual B) optionally measuring the concentration of one or more other heart failure markers in the sample; and c) the concentration measured in step (a) and optionally step (b) By comparing the concentration (s) measured in step 1 with this marker or the concentration of these markers established in a control sample, the risk of the subject suffering from heart failure is predicted. The method is further characterized in that the one or more other markers are selected from the group consisting of cardiac troponin marker, GDF-15 and insulin growth factor binding protein (IGFBP7). In a preferred embodiment of the invention, the subject is suffering from left ventricular diastolic dysfunction. The present invention also relates to a method for determining treatment of a subject carrying a risk factor for developing heart failure and a method for monitoring the treatment. In a preferred embodiment of the invention, the at least one other marker is selected from cardiac troponin, GDF-15 and IGFBP7. The present invention further relates to a method for monitoring treatment of an abnormality of cardiac function and / or structure prior to heart failure in a subject comprising the following steps: a) at least one in at least one sample of the subject The concentration of one type of cardiac troponin is measured repeatedly within a specified time interval; b) optionally the concentration of one or more other heart failure markers in the sample; and c) measured in step (a) Comparing the concentration and optionally the concentration (s) measured in step (b) to this marker or the concentration of these markers established in a control sample; and c) in one or more of the markers indicated above Based on the difference in measured concentrations, it is assessed whether the subject has changed its pathophysiological state. [Selection] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017512988-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7045349-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-6995898-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019164160-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7114677-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020202241-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021043218-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020089746-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017536537-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019514026-A |
| priorityDate | 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 562.